Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.com

StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report issued on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

A number of other research analysts have also issued reports on RVNC. HC Wainwright reiterated a “neutral” rating and set a $6.60 price target on shares of Revance Therapeutics in a research note on Friday, November 8th. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, November 8th. Barclays reissued an “equal weight” rating and issued a $7.00 price target (down from $10.00) on shares of Revance Therapeutics in a report on Friday, September 13th. Finally, Mizuho dropped their price objective on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday. Nine research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $8.96.

Revance Therapeutics Stock Up 1.6 %

Revance Therapeutics stock opened at $3.09 on Thursday. The stock has a 50 day moving average of $4.60 and a two-hundred day moving average of $4.46. Revance Therapeutics has a twelve month low of $2.30 and a twelve month high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The company had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $67.73 million. Analysts predict that Revance Therapeutics will post -1.57 earnings per share for the current fiscal year.

Institutional Trading of Revance Therapeutics

A number of institutional investors have recently bought and sold shares of RVNC. Certuity LLC acquired a new position in shares of Revance Therapeutics during the 2nd quarter worth $26,000. Vanguard Personalized Indexing Management LLC acquired a new position in Revance Therapeutics during the second quarter worth about $33,000. Hsbc Holdings PLC purchased a new stake in shares of Revance Therapeutics in the second quarter valued at about $38,000. Nisa Investment Advisors LLC grew its position in shares of Revance Therapeutics by 2,167.5% in the second quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 18,077 shares during the last quarter. Finally, FORA Capital LLC acquired a new stake in shares of Revance Therapeutics in the third quarter valued at approximately $54,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.